

The Evolving Landscape of Artificial Intelligence in Cancer Research & Precision Medicine: Emerging Trends, Challenges and Opportunities

Jayendrakumar B. Patel^{1,2}, Disha D. Jethva^{1,2}, Kinjal K. Gajjar^{1,2},
Toral H. Mandalia^{1,2}, Hemangini Vora²

¹Molecular Diagnostics & Research Laboratory-2,²Department of Cancer Biology,
The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad -380 016, Gujarat, India.

Corresponding Author: Jayendrakumar B. Patel

DOI: <https://doi.org/10.52403/ijhsr.20250213>

ABSTRACT

Artificial Intelligence (AI) incorporates a broad spectrum of technologies and methodologies that utilized mathematical algorithms to replicate human cognitive functions, such as learning, reasoning, problem-solving and decision making. The remarkable expansion of AI over the past decade highlights its potential advantages, particularly through the global adoption of Machine Learning, Deep Learning, Explainable AI and Generative AI. This evolution highlights the transformative potential of AI across various sectors, particularly in healthcare, where it is poised to revolutionize patient care and medical research. This review focused on uncovering the impact of AI in cancer research and precision medicine, where AI technologies are being integrated with cancer biology to enhance the understanding of disease and improve treatment outcomes. The merging of AI with cancer research allows for the analysis of complex biological data, enabling researchers to identify patterns and correlations that may not be immediately apparent through traditional methods. For instance, AI algorithms can process genomic data, clinical records, and imaging studies to uncover insights into tumor behavior, treatment responses, and patient prognoses. Moreover, current review also emphasized on improving AI models, addressing clinical integration challenges and ensuring unbiased access for all cancer patients. These efforts could significantly enhance cancer diagnosis, treatment and outcomes, leading to a new era of precision oncology.

Keywords: Artificial Intelligence, Cancer Research, Precision Medicine

INTRODUCTION

The ability of a machine to carry out tasks like learning, thinking, and problem-solving that are typically considered to be intelligent human behaviours is known as **Artificial Intelligence (AI)**. Algorithms that allow data to be used to generate new content or make predictions are the source of this capability in computers. Artificial

intelligence (AI) algorithms are able to find links between data points and recognize patterns in vast amounts of data that are difficult for the human brain to understand. ^[1] The potential advantages of AI are shown by its quick development over the last 10 years, particularly with the widespread use of machine learning, deep learning, explainable AI, and generative AI. **Machine**

Learning (ML) is a method that enables a computer to recognize patterns, enhance the accuracy of its predictions, and improve its performance through experience, all without the need for explicit programming. This technology is employed in the development of applications powered by artificial intelligence. The implementation of this process relies on various ML methodologies. **Deep learning (DL)** uses algorithms inspired by the human brain's structure to create intelligent models through artificial neural networks. It processes both structured and unstructured data, powering applications like virtual assistants (Siri, Alexa) and facial recognition systems. DL is also crucial in medical research and predicting life-threatening diseases. **Explainable AI (XAI)** is a field of artificial intelligence focused on making the decision-making processes of AI models transparent and understandable to users. Traditional AI models, particularly those based on complex algorithms like deep learning, often operate

as "black boxes," where the rationale behind their predictions or decisions is not easily discernible. This lack of transparency can lead to mistrust, especially in critical applications such as healthcare, finance, and autonomous systems, where understanding the reasoning behind a decision is crucial. XAI aims to bridge this gap by elucidating the internal workings of these models. It does so by providing insights into how the model processes input data, the features it considers important, and the logic it employs to arrive at specific outcomes. [2] **Generative AI** has now become a key area of advancement in artificial intelligence. This technology autonomously creates new content from input data, utilizing machine learning, natural language processing, image processing, and computer vision. Machine learning is essential for generative AI, as it enables computers to learn from large datasets and produce diverse content through both discriminative models, which classify data, and generative models, which create new data. [2-3] (Figure 1)




Figure 1. The connection between the Artificial-Intelligence, Machine-Learning, Deep-Learning Explainable Artificial Intelligence and Generative Artificial Intelligence.

The typical workflow involved in developing an AI-based system, particularly in the context of cancer research and diagnostics or similar applications is illustrated in **Figure 2**.




Figure 2. Briefly illustrates the workflow of Artificial Intelligence

Below is a brief explanation of each step:

1. Raw Data Collection: This initial stage involves gathering diverse data types such as medical images (e.g., X-rays, MRIs), clinical records, or genomic data. The quality and quantity of data play a crucial role in AI model performance.

2. Data Processing: Raw data often require cleaning and pre-processing, including handling missing values, normalizing data, and enhancing datasets. In medical AI, this could involve labelling data or enhancing images to improve diagnostic accuracy.

3. Model Selection: This step involves choosing an appropriate AI model architecture, such as neural networks, decision trees, or support vector machines, based on the problem and the dataset characteristics.

4. Training the Model: The selected model is trained using the processed data. During training, the model learns patterns and relationships in the data to make accurate predictions or classifications.

5. Testing of Model: Once trained, the model is evaluated on a separate testing dataset to measure its accuracy, sensitivity, specificity, and generalizability to new data.

6. Evaluation: The final stage involves assessing the model's overall performance using various metrics like precision, recall, F1 score, and area under the ROC curve (AUC). This step may also include repeated fine-tuning to optimize the model for real-world applications. This workflow underscores the systematic approach necessary for developing robust AI systems that can be applied to critical areas such as cancer research and Precision Medicine.

ROLE OF ARTIFICIAL INTELLIGENCE IN DIGITAL HEALTH CARE:

Recent years have seen a surge in interest and advancement in digital healthcare settings, fuelled by improved computing power and the availability of digital data. AI is revolutionizing research by analysing

large datasets to identify patterns that humans might miss. In healthcare, AI has enabled the creation of diagnostic tools and personalized treatment plans. Its rapid advancement presents an opportunity to transform clinical practice, enhancing patient care and outcomes. AI-driven predictive analytics can improve the accuracy, efficiency and cost-effectiveness of diagnosis and lab tests, while also aiding in population health management and clinical decision making. Additionally, AI

shows promise in virtual and mental health services, further improving patient care. It help identify new pharmaceuticals and manage extensive medical data. AI also has the potential to reduce healthcare costs and streamline tasks, further research is needed to validate its effectiveness in the medical sector.^[4-6] The following subsections seek to clarify the topics concerning the utilization of AI approaches in healthcare. All of them are demonstrated in (Figure 3).




Figure 3. Applications of Artificial Intelligence in Digital Healthcare

Health Services and Management:

Artificial intelligence has the potential to alleviate administrative workloads by automatically filling in structured data fields from therapeutic notes, extracting essential information from historical medical records, and gathering documented patient interactions.^[7] By utilizing natural language processing (NLP) algorithms, AI systems analyse notes and automatically fill relevant areas with accurate patient demographics, treatment plans and medication details. This saves time for healthcare professionals,

reduces the risk of human error in data entry and provide possibly real-time medical information. Hence, AI applications allow hospitals and healthcare services to function more efficiently for various reasons including: i.) Clinicians can quickly access essential data ii.) Nurses can improve patient safety when administering medications iii.) Patients can stay informed and engage actively in their care by keeping in touch with their medical teams during their hospital stays.^[5]

Predictive medicine:

A crucial area of interest is the use of artificial intelligence in disease prediction, diagnosis, treatment and prognosis. AI's ability to identify patterns in data enhances diagnostic processes and treatment strategies, allowing healthcare professionals to proactively manage diseases. It also helps identify patient-specific risk factors for targeted interventions, improving outcomes. Overall, AI has the potential to transform medicine by creating predictive models for lifelong patient monitoring.^[5]

Medical Research and Drug Discovery:

AI is highly effective at analysing intricate medical research datasets, enabling the identification of research initiatives, integration of various data types, and fostering drug innovation. Pharmaceutical companies are increasingly leveraging AI to optimize drug development processes, utilizing predictive analytics to choose clinical trial candidates and model biological mechanisms. Machine learning improves the pre-trial phase by organizing participants and managing data, thereby enhancing the efficiency and success rates of trials. Generative AI can produce synthetic data to enrich datasets and enhance diversity, while metaverse applications facilitate collaboration among researchers in a virtual setting. Progress in AI, machine learning, bioinformatics, and cheminformatics is lowering the costs and duration of drug discovery by identifying compounds, validating drug targets, and assisting in the repurposing of existing drugs for clinical trials.^[7]

Medical Imaging, Patient data and Diagnostics:

AI methodologies can help medical researchers manage the vast amounts of data generated by patients, known as medical big data. These systems process data from clinical activities like screening, diagnosis, and treatment allocation, enabling healthcare professionals to identify patterns and correlations between patient

characteristics and outcomes. AI can enhance patient care by providing valuable insights, aiding in diagnostics, and offering rapid assessments of overall health. Additionally, AI can create three-dimensional maps of a patient's anatomy. Emerging research focuses on managing and protecting patient data in AI applications. In diagnostics, AI has the potential to improve rehabilitation therapy and surgical procedures, with various robotic systems developed for these purposes.^[5]

Clinical Decision Making:

AI applications significantly enhance clinical decision-making for healthcare professionals, including doctors and researchers. By improving clinical decisions, AI can supplement or even replace human judgment in certain areas, expediting decision-making and increasing care volume, which positively impacts healthcare costs. Research in computer-aided diagnostics shows high sensitivity, accuracy and specificity in detecting subtle radiographic anomalies, improving public health outcomes.^[5, 7]

Virtual Patient Care:

The integration of virtual care through advanced and practical wearable technology solutions has become an important aspect of patient monitoring and management. The utilization of modern technologies such as artificial intelligence, telepresence, blockchain, Virtual Reality (VR), Augmented Reality (AR) and digital twinning offers innovative approaches to delivering cost-effective management that enhances patient outcomes. Remote Patient Monitoring (RPM), a component of telehealth, enables healthcare professionals to observe, assess and document patient conditions outside of conventional settings. RPM facilitates medical interventions by employing sensors and communication technologies, thereby simplifying the process of remotely analysing health data or addressing patient concerns. Additionally, it

empowers patients to actively participate in understanding and managing their health conditions. [7]

IMPLEMENTATION OF ARTIFICIAL INTELLIGENCE METHODS IN CANCER RESEARCH AND PRECISION MEDICINE:

Cancer treatment today offers various options, with significant improvements in effectiveness since the 2010s. However, achieving satisfactory outcomes for all patients remains difficult due to diagnostic uncertainties. Accurate prognostic assessments could enable personalized treatment plans, reducing the physical and psychological burdens of the illness. The incorporation of AI into cancer care is anticipated to significantly transform the current landscape, similar to trends observed in various other healthcare sectors. Advancements in AI technology present challenges for clinical researchers, but collaboration between computer engineers and health scientists has improved prognostic capabilities through multi-factor analysis and statistical methods. These approaches have outperformed traditional predictions. AI can enhance predictive modeling and early detection by examining a variety of data sources, such as electronic health records, genetic information, and environmental influences, to evaluate an individual's risk of developing cancer and to tailor prevention strategies accordingly. Recently, there has been a growing application of AI algorithms in creating models for cancer prediction and diagnosis, which improves the precision of assessing susceptibility, recurrence, and survival rates. Moreover, AI have the potential to lower screening expenses, enhance diagnostic accuracy, improve prognostic assessments, and support the development of new pharmaceuticals. Numerous domains within cancer care, such as cancer radiology and clinical oncology, are projected to gain advantages from the implementation of AI

technologies. [8, 9] **Figure 4** show the implementation of AI in cancer research and precision medicine.

AI-Driven Multiomics: Transforming Cancer Diagnosis, Prognosis, and Treatment:

The rise of multiomics technology—encompassing genomics, proteomics, transcriptomics, and metabolomics—has transformed cancer diagnosis, prognosis, and treatment. However, the complexity and volume of omics data create opportunities for AI and machine learning (ML) to establish clinical correlations. Various ML methods, including supervised, unsupervised, and reinforcement learning, are used to analyze multiomics data for predictions related to early detection, recurrence, prognosis, risk stratification, and subtyping in cancer. Additionally, ML techniques help reduce the dimensionality of omics data, improving predictions of responses to chemotherapy, targeted therapy, and immunotherapy. [10]

Convolutional Neural Networks for Early Cancer Detection and Image Analysis:

AI in tumor histopathology and radiological imaging aids in early detection, diagnosis, sub-typing, staging, grading, and prognostic prediction. A random forest classifier has been used for early identification of eight cancer types via a simple blood test. Convolutional neural networks (CNNs) differentiate malignant tumors from benign lesions in breast, colorectal, and gastric cancers using imaging slides. CNNs are popular for cancer image classification, performing nonlinear transformations to learn relevant features. Two main methodologies exist: transfer learning, which uses large natural image datasets to train initial layers before fine-tuning with disease-specific data, and autoencoders, which learn background features from a subset of images to initialize the CNN. [11, 12]




Figure 4: AI in Cancer Care including Diagnosis, Treatment, Early Screening, Tumor Staging Clinical Decision-Making and Prognosis

Deep Neural Networks: Revolutionizing Cancer Diagnosis Precision:

Deep neural networks (DNNs) represent advanced algorithms capable of processing large images, such as whole slide images (WSIs) stained with hematoxylin and eosin (H&E), provided that sufficient computational resources are available. These model architectures have demonstrated remarkable proficiency in image classification tasks, including the identification of cancer cells within digitized stained slides. Achieving exceptional prediction accuracies in differentiating tumor cells from healthy ones (AUCs > 0.99), DNNs are also employed in more complex classification challenges, such as distinguishing between closely related cancer subtypes and differentiating benign tissue from malignant tissue. The effectiveness of Deep Neural

Networks (DNNs) is not limited to histopathological images; it also encompasses various medical images obtained through noninvasive methods, including CT scans, MRI, and mammograms, as well as images of potentially concerning lesions.^[11, 13] If future studies validate these models, they could greatly enhance early cancer detection and classification, matching or surpassing expert performance. AI-driven smartphone apps are also emerging for identifying cancerous lesions outside hospitals, but their diagnostic accuracy still requires clinical validation.^[11, 14]

Next Generation Sequencing to Artificial Intelligence: Revolutionizing Precision Medicine and Genomic Research:

There is an increasing trend to use non-imaging data, such as genomic profiles, for cancer diagnostics and staging. Next-

generation sequencing (NGS) data—including whole exome, whole-genome, targeted panels, and transcription profiles—can aid in cancer diagnosis and tumor classification. However, identifying genetic variants from NGS is challenging due to error rates ranging from 0.1% to 10%, influenced by sequencing instruments, data processing, and the genomic sequence itself. Many studies have led to the development of AI-based tools to improve NGS capabilities. The evolution of DNA sequencing from Sanger sequencing to NGS has covered the way for AI to play a crucial role in managing and analyzing the vast genomic data generated. Additionally, given the multidimensional nature of this data, statistical methods or machine learning techniques are essential for effective cancer classification. [15] An AI-based classifier, which was trained on the most prevalent cancer-specific point mutations derived from whole-exome sequencing profiles, demonstrated a high level of accuracy (AUC, 0.94) in differentiating between healthy and tumor tissues. However, its performance in a multiclass classification task, aimed at distinguishing all 12 cancer types simultaneously, was less effective (AUC, 0.70). Additionally, a significant area of exploration for AI lies in the identification of specific key mutations directly from histopathology images, particularly those mutations that are clinically actionable and serve as response biomarkers for targeted therapies. This approach could provide a more cost-effective and expedited alternative to mutation detection through NGS. [11]

NAVIGATING THE CHALLENGES OF CLINICAL WORKFLOW INTEGRATION:

Incorporating AI into clinical practice poses several challenges, mainly due to the lack of standardization in cancer-related health data. These issues can hinder the testing, validation, certification, and auditing processes for AI algorithms and systems. [9]

The successful incorporation of artificial intelligence in oncology hinges on its effective integration into clinical workflows, a process that poses both logistical and scientific hurdles. Implementing AI applications requires substantial computational resources, whether on-site or cloud-based, along with the expertise of highly skilled engineers. This requirement is likely to further strain already limited healthcare information technology budgets. In addition to the initial hardware requirements, it is essential to establish data pipelines that can efficiently direct data to AI systems and ensure that the resulting insights are accessible to clinicians. Achieving such integration into clinical systems can be particularly difficult when dealing with registered systems that offer restricted customization options. [16] Numerous AI tools are likely to prove ineffective in combating cancer unless they are made accessible and comprehensible to biologists, oncologists and other medical cancer researchers. The successful incorporation of AI research into conventional clinical practices requires collaboration among researchers, healthcare practitioners and regulatory bodies. [17, 18] Future research should concentrate on incorporating explainable artificial intelligence (XAI) methods that emphasize fairness and transparency in predictions. XAI offers clear explanations for AI decisions, which helps build user trust. Additionally, studies should explore federated learning, a technique that trains models on decentralized datasets without the need to share raw data, thereby improving prediction accuracy while safeguarding privacy. The integration of XAI with federated learning in cancer diagnostics presents a promising opportunity to enhance both accuracy and clarity in decision-making. Furthermore, upcoming research must address the ethical and regulatory aspects of these technologies, creating guidelines for data privacy, patient consent, and algorithmic fairness in clinical settings. [16, 19] AI models have the potential

to impact the cancer diagnostic market; however, for treatment purposes, they need to be combined with the knowledge of medical professionals and clinical data. [20]

CONCLUSION: FROM INSIGHT TO ACTION:

The integration of AI into cancer diagnostics represents a transformative leap forward in the fight against cancer. As AI technologies continue to evolve, they hold immense promise in enhancing diagnostic accuracy, improving early detection, and personalizing treatment plans. The use of machine learning, deep learning, and generative AI is enabling healthcare professionals to analyze complex datasets, including medical imaging, genomic profiles, and clinical histories, to identify patterns and insights that were previously difficult to uncover. However, several challenges persist, including data standardization, integration into clinical workflows, and the need for transparency in AI decision-making, particularly through the adoption of Explainable AI (XAI) techniques. Furthermore, ethical considerations around patient privacy, data security, and algorithmic fairness remain critical areas that require careful attention as AI systems become more embedded in clinical settings.

Despite these hurdles, the opportunities presented by AI in cancer diagnostics are vast. From improving early detection rates through advanced imaging techniques to aiding in the discovery of new drug therapies and precision medicine, AI is reshaping the landscape of cancer care. The growing use of multi-modal data, including genomics, proteomics, and imaging, provides a holistic approach to understanding cancer biology and developing targeted treatment strategies. Moving forward, continued collaboration between AI experts, clinicians, and researchers will be essential to harness the full potential of AI in cancer diagnostics. Research should focus on refining AI models, addressing clinical integration

challenges, and ensuring that these technologies are accessible, fair, and beneficial to all patients. With these efforts, AI has the potential to significantly improve cancer diagnosis, treatment, and outcomes, leading in a new era of precision oncology.

Declaration by Authors

Ethical Approval: Not Applicable

Acknowledgement: The authors gratefully acknowledge The Gujarat Cancer & Research Institute for providing the necessary resources and support to carry out this review.

Conflict of Interest: The authors declare no conflict of interest.

REFERENCES

1. National Cancer Institute. AI and Cancer - NCI [Internet]. www.cancer.gov. 2024. Available from: <https://www.cancer.gov/research/infrastructure/artificial-intelligence>
2. Saranya A, Subhashini R. A systematic review of Explainable Artificial Intelligence models and applications: Recent developments and future trends. *Decision Analytics Journal* 7 (2023), 100230 [Internet]. 2023
3. Lv Z. Generative artificial intelligence in the metaverse era. *Cognitive Robotics*. 2023 Jan 1; 3:208-17.
4. Alowais SA, Alghamdi SS, Alsuhebany N, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. *BMC medical education*. 2023 Sep 22;23(1):689.
5. Secinaro S, Calandra D, Secinaro A, et al. The role of artificial intelligence in healthcare: a structured literature review. *BMC medical informatics and decision making*. 2021 Dec; 21:1-23.
6. Chang A. The role of artificial intelligence in digital health. *InDigital health entrepreneurship* 2023 Sep 5 (pp. 75-85). Cham: Springer International Publishing.
7. Al Kuwaiti A, Nazer K, Al-Reedy A, et al. A review of the role of artificial intelligence in healthcare. *Journal of personalized medicine*. 2023 Jun 5;13(6):951.
8. Huang S, Yang J, Fong S, et al. Artificial intelligence in cancer diagnosis and

- prognosis: Opportunities and challenges. *Cancer letters*. 2020 Feb 28; 471:61-71.
9. Cabral BP, Braga LA, Syed-Abdul S, et al. Future of artificial intelligence applications in cancer care: a global cross-sectional survey of researchers. *Current Oncology*. 2023 Mar 16;30(3):3432-46.
 10. Arjmand B, Hamidpour SK, Tayanloo-Beik A, et al. Machine learning: a new prospect in multi-omics data analysis of cancer. *Frontiers in Genetics*. 2022 Jan 27; 13:824451.
 11. Bhinder B, Gilvary C, Madhukar NS, et al. Artificial intelligence in cancer research and precision medicine. *Cancer discovery*. 2021 Apr 1;11(4):900-15.
 12. Dankwa-Mullan I, Weeraratne D. Artificial intelligence and machine learning technologies in cancer care: addressing disparities, bias, and data diversity. *Cancer Discovery*. 2022 Jun 2;12(6):1423-7.
 13. Djuric U, Zadeh G, Aldape K, et al. Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care. *NPJ precision oncology*. 2017 Jun 19;1(1):22.
 14. Freeman K, Dinnes J, Chuchu N, et al. Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies. *bmj*. 2020 Feb 10;368.
 15. Alagarwamy K, Shi W, Boini A, et al. Should AI-Powered Whole-Genome Sequencing Be Used Routinely for Personalized Decision Support in Surgical Oncology—A Scoping Review. *BioMedInformatics*. 2024 Jul 24;4(3):1757-72.
 16. Lotter W, Hassett MJ, Schultz N, et al. Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions. *Cancer Discovery*. 2024 May 1;14(5):711-26.
 17. Alsharif F. Artificial Intelligence in Oncology: Applications, Challenges and Future Frontiers. *International Journal of Pharmaceutical Investigation*. 2024 Jul 1;14(3).
 18. Sebastian AM, Peter D. Artificial intelligence in cancer research: trends, challenges and future directions. *Life*. 2022 Nov 28;12(12):1991.
 19. Abbas S, Asif M, Rehman A, et al. Emerging research trends in artificial intelligence for cancer diagnostic systems: A comprehensive review. *Heliyon*. 2024 Aug 23.
 20. Zhang C, Xu J, Tang R, et al. Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment. *Journal of Hematology & Oncology*. 2023 Nov 27;16(1):114.
- How to cite this article: Jayendrakumar B. Patel, Disha D. Jethva, Kinjal K. Gajjar, Toral H. Mandalia, Hemangini Vora. The evolving landscape of artificial intelligence in cancer research & precision medicine: emerging trends, challenges and opportunities. *Int J Health Sci Res*. 2025; 15(2):106-115. DOI: <https://doi.org/10.52403/ijhsr.20250213>
